Therapeuticsmd incorporated TXMD.US 總覽分析

美股醫療保健
(TXMD 無簡報檔)

TXMD 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

TXMD 近期報酬表現

1.25%

Therapeuticsmd incorporated

1.31%

同產業平均

0.58%

S&P500

與 TXMD 同產業的標的表現

  • ABVX Abivax sa - adr
    價值 -趨勢 3 分波段 4 分籌碼 3 分股利 1 分
    查看更多

TXMD 公司資訊

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

TXMD 股價